ASPIRIN

/static/temp/default.svg Search structure
Trade Names
Synonyms
Status
Molecule Category Free-form
UNII R16CO5Y76E
EPA CompTox DTXSID5020108

Structure

InChI Key BSYNRYMUTXBXSQ-UHFFFAOYSA-N
Smiles CC(=O)Oc1ccccc1C(=O)O
InChI
InChI=1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)

Physicochemical Descriptors

Property Name Value
Molecular Formula C9H8O4
Molecular Weight 180.16
AlogP 1.31
Hydrogen Bond Acceptor 3.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 2.0
Polar Surface Area 63.6
Molecular species ACID
Aromatic Rings 1.0
Heavy Atoms 13.0

Metabolites Network

visNetwork

Bioactivity

Mechanism of Action Action Reference
Cyclooxygenase inhibitor INHIBITOR PubMed PubMed Wikipedia
Protein: Cyclooxygenase
Description: Prostaglandin G/H synthase 1
Organism : Homo sapiens
P23219 ENSG00000095303
Protein: Cyclooxygenase
Description: Prostaglandin G/H synthase 2
Organism : Homo sapiens
P35354 ENSG00000073756
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Cytochrome P450 Cytochrome P450 family 5 Cytochrome P450 family 5A Cytochrome P450 5A1
- - - - 100-100
Enzyme Hydrolase
- - - - 90
Enzyme Oxidoreductase
- 300-100000 - 52000 22-80
Enzyme
- 300-100000 - 52000 22-80
Membrane receptor
- 5000 - - -
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides
- - - - 96
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC22 family of organic cation and anion transporters
- - - -
Assay Description Organism Bioactivity Reference
Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM Rattus norvegicus 0.0 %
Inhibition of CCl4 induced lipid peroxidation (LPO) of guinea pig hepatic microsomes at 300 uM concentration Cavia porcellus 4.0 %
Inhibition of ADP-induced platelet aggregation in human platelet rich plasma at 10e-5 M Homo sapiens 20.0 %
Inhibition of ADP-induced platelet aggregation in guinea pig whole blood at 5*10e-3 M Cavia porcellus 15.0 %
Inhibition of arachidonic acid induced platelet aggregation in guinea pig whole blood at 5*10e-3 M Cavia porcellus 30.0 %
Inhibition of adrenaline induced platelet aggregation in human platelet rich plasma at 10e-5 M Homo sapiens 38.3 %
In vitro inhibition of collagen-induced platelet aggregation in human platelet rich plasma Homo sapiens 10.0 ug.mL-1
Compound was evaluated for the inhibitory activity against human platelet aggregation by COL/ADP cartridges at a concentration of 1 x 10 e-3 M Homo sapiens 0.0 %
Compound was evaluated for the inhibitory activity against human platelet aggregation by COL/ADP cartridges at a concentration of 2 x 10 e-3 M Homo sapiens 0.0 %
Compound was evaluated for the inhibitory activity against human platelet aggregation by COL/ADP cartridges at a concentration of 3 x 10 e-3 M Homo sapiens 0.0 %
Compound was evaluated for the inhibitory activity against human platelet aggregation by COL/ADP cartridges at a concentration of 4 x 10 e-3 M Homo sapiens 6.76 %
Compound was evaluated for the inhibitory activity against human platelet aggregation by COL/ADP cartridges at a concentration of 5 x 10 e-3 M Homo sapiens 17.12 %
Inhibition of ADP-induced platelet aggregation in guinea pig whole blood at 5*10e-4 M Cavia porcellus 100.0 %
Inhibition of arachidonic acid induced platelet aggregation in guinea pig whole blood at 5*10e-4 M Cavia porcellus 100.0 %
Inhibition of arachidinoc acid induced platelet in human platelet rich plasma at 10e-5 M Homo sapiens 90.0 %
Inhibition of collagen induced platelet aggregation in human platelet rich plasma at 10e-5 M Homo sapiens 52.0 %
Compound was screened for its platelet aggregation induced by TXA2 mimetics I-BOP in vitro in human platelets at conc 10 mM Homo sapiens 43.0 %
Compound was screened for its platelet aggregation induced by TXA2 mimetics U-46,619 in vitro in human platelets at conc 1 mM Homo sapiens 28.0 %
Compound was screened for its platelet aggregation induced by arachidonic acid in vitro in human platelets at conc 30 mM Homo sapiens 96.0 %
Compound was screened for its platelet aggregation induced by collagen in vitro in human platelets at conc 1 mM Homo sapiens 94.0 %
In vitro inhibition of human platelet aggregation induced by 10 uM ADP after incubation at 100 uM Homo sapiens 31.2 %
In vitro inhibition of human platelet aggregation induced by 10 uM ADP after incubation at 150 uM Homo sapiens 37.1 %
In vitro inhibition of human platelet aggregation induced by 10 uM ADP after incubation at 200 uM Homo sapiens 48.5 %
In vitro inhibition of human platelet aggregation induced by 10 uM ADP after incubation at 250 uM Homo sapiens 56.4 %
Inhibition of acetic acid induced writhing in mice at dose of 100 mg/kg Mus musculus 61.7 %
Inhibition of acetic acid induced writhing in mice at dose of 200 mg/kg Mus musculus 74.0 %
Inhibition of acetic acid induced writhing in mice at dose of 50 mg/kg Mus musculus 38.2 %
Analgesic activity in mice using phenylquinone writhing test at 50 mg/kg, sc dose Mus musculus 50.0 %
Analgesic activity was measured on phenylquinone writhing in mice at 50 mg/kg subcutaneous dose Mus musculus 50.0 %
Analgesic activity was measured by phenylquinone writhing test in male Swiss albino mice at a dose of 50 mg/Kg, sc. Mus musculus 50.0 %
In vivo anti-thrombotic activity was evaluated by the inhibition of pulmonary thromboembolism model in mice at a dose of 30 mg/kg (p.o.) Mus musculus 33.0 %
Effect on PGI-2 release from rat aortic tissue at a final concentration of 10e -4 for an incubation time of 10 minutes Rattus norvegicus 80.0 %
Effect on PGI-2 release from rat aortic tissue at a final concentration of 10e -4 for an incubation time of 25 minutes Rattus norvegicus 80.0 %
Effect on PGI-2 release from rat aortic tissue at a final concentration of 10e -4 for an incubation time of 30 minutes Rattus norvegicus 80.0 %
Effect on PGI-2 release from rat aortic tissue at a final concentration of 10e -4 for an incubation time of 35 minutes Rattus norvegicus 80.0 %
In vitro inhibitory activity of collagen (0.8 ug/mL)-induced platelet aggregation in guinea pig platelet rich plasma at a dose of 0.8 ug/mL Cavia porcellus 75.0 %
In vitro inhibitory activity of thrombin (0.625 IU/mL)-induced platelet aggregation in guinea pig platelet rich plasma after 4 min Cavia porcellus 0.0 %
In vitro irreversible inhibitory activity of adenosine diphosphate (0.5 uM)-induced platelet aggregation in guinea pig platelet rich plasma Cavia porcellus 100.0 %
In vitro reversible inhibitory activity of adenosine diphosphate (0.5 uM)-induced platelet aggregation in guinea pig platelet rich plasma Cavia porcellus 0.0 %
Inhibitory activity of thrombin (0.625 IU/mL)-induced platelet aggregation in guinea pig platelet rich plasma after 2 min Cavia porcellus 0.0 %
Percentage inhibition against platelet activating factor (2 ng/mL) induced platelet aggregatory activity None 2.0 %
Percentage inhibition against thrombin induced platelet aggregatory activity None 81.0 %
Inhibition of Prostaglandin G/H synthase 2 from sheep placenta at 300 uM Ovis aries 0.0 %
In vitro inhibition of collagen-induced platelet aggregation in human platelet-rich plasma (PRP) Homo sapiens 10.0 ug.mL-1
Inhibition of Prostaglandin G/H synthase 1 isolated from ram (sheep) seminal vesicle at 300 uM Ovis aries 76.0 %
Compound was tested for antiinflammatory activity and the % inhibition was reported 3 hr after carrageenan injection in the hind paw edema test in rats: dose=80 mg/kg Rattus norvegicus 25.8 %
Compound was tested for antiinflammatory activity in rats by adjuvant arthritis test after peroral administration of 50 mg/kg dose Rattus norvegicus 32.0 %
Compound was tested for antiinflammatory activity in rats by carrageenam edema test after peroral administration of 200 mg/kg dose Rattus norvegicus 40.0 %
% inhibition of acetic acid-induced writhing in rat at 30 mg/kg peroral dose, 120 min postdose(5 rats per compound at each time) Rattus norvegicus 26.0 %
% inhibition of acetic acid-induced writhing in rat at 30 mg/kg peroral dose, 15 min postdose(5 rats per compound at each time) Rattus norvegicus 53.0 %
% inhibition of acetic acid-induced writhing in rat at 30 mg/kg peroral dose, 180 min postdose(5 rats per compound at each time) Rattus norvegicus 18.0 %
% inhibition of acetic acid-induced writhing in rat at 30 mg/kg peroral dose, 30 min postdose(5 rats per compound at each time) Rattus norvegicus 37.0 %
% inhibition of acetic acid-induced writhing in rat at 30 mg/kg peroral dose, 360 min postdose(5 rats per compound at each time) Rattus norvegicus 0.0 %
% inhibition of acetic acid-induced writhing in rat at 30 mg/kg peroral dose, 60 min postdose(5 rats per compound at each time) Rattus norvegicus 60.0 %
In vivo inhibitory activity after 120 min of 100 mg/kg oral administration induced by I-BOP in rats Rattus norvegicus 0.9 %
In vivo inhibitory activity after 120 min of 100 mg/kg oral administration induced by arachidonic acid in rats Rattus norvegicus 93.8 %
In vivo inhibitory activity after 120 min of 100 mg/kg oral administration induced by collagen in rats Rattus norvegicus 84.6 %
Compound was evaluated for its antiinflammatory activity in the cotton pellet induced granuloma(CPG) in normal rats at the dose 50 mg/kg p.o. Rattus norvegicus 24.0 %
In vivo anti-hyperplastic activity was evaluated by the inhibition of balloon injury model in rats at a dose of 30 mg/kg (p.o.) Rattus norvegicus 16.0 %
Effect on thromboxane synthetase activity on ex vivo platelet aggregation induced by TXB2 at 100 mg/kg expressed as percent increase Cavia porcellus 100.0 %
Effect on thromboxane synthetase activity on ex vivo platelet aggregation induced by TXB2 at 50 mg/kg expressed as percent increase Cavia porcellus 100.0 %
Effect on thromboxane synthetase activity on in vitro platelet aggregation induced by AA at 10e -5 M expressed as percent increase in TXB2 None 100.0 %
In vitro inhibition of collagen-induced human platelet aggregation. Homo sapiens 494.0 ug.mL-1
Ex vivo inhibition of platelet aggregation induced by AA at 100 mg/kg Homo sapiens 100.0 %
Ex vivo inhibition of platelet aggregation induced by AA at 50 mg/kg Homo sapiens 100.0 %
Ex vivo inhibition of platelet aggregation induced by ADP-II at 100 mg/kg Homo sapiens 100.0 %
Ex vivo inhibition of platelet aggregation induced by ADP-II at 50 mg/kg Homo sapiens 100.0 %
In vitro inhibitory concentration against COX-1 enzyme Ovis aries 300.0 nM
In vitro inhibition of ovine prostaglandin G/H synthase 1 Ovis aries 350.0 nM
Percent inhibition of cyclooxygenase activity of compound at 10 uM concentration Oryctolagus cuniculus 99.0 %
Inhibitory concentration against human cyclooxygenase-1 at 200 uM concentration Homo sapiens 80.0 %
Inhibitory activity against ovine COX1 Ovis aries 350.0 nM
Inhibitory activity against 4% NaCl-induced abdominal constriction in Sprague-Dawley rat after 30 min of 30 mg/kg, po Rattus norvegicus 29.7 %
Inhibitory activity against 4% NaCl-induced abdominal constriction in Sprague-Dawley rat after 60 min of 30 mg/kg, po Rattus norvegicus 46.4 %
Inhibition of COX1 at 30 uM None 21.9 %
Inhibition of COX2 at 30 uM None 15.7 %
Analgesic activity in Swiss Albino mouse assessed as inhibition of acetic acid-induced writhing responses at 100 mg/kg, ip Mus musculus 97.0 %
Inhibition of p-benzoquinone-induced writhing in Swiss albino mouse at 100 mg/kg, po relative to control Mus musculus 55.2 %
Inhibition of p-benzoquinone-induced writhing in Swiss albino mouse at 200 mg/kg, po relative to control Mus musculus 53.6 %
Inhibition of ovine COX1 by enzyme immuno assay Ovis aries 300.0 nM
Inhibition of p-Benzoquinone-induced writhings in Swiss Albino mouse at 100 mg/kg, po relative to control Mus musculus 54.3 %
Antiinflammatory activity in rat assessed as inhibition of formalin-induced paw oedema at 100 mg/kg, ip Rattus norvegicus 5.97 %
Antiinflammatory activity in rat assessed as inhibition of formalin-induced paw oedema at 100 mg/kg, ip after 0.5 hrs Rattus norvegicus 9.76 %
Antiinflammatory activity in rat assessed as inhibition of formalin-induced paw oedema at 100 mg/kg, ip after 1 hr Rattus norvegicus 17.08 %
Antiinflammatory activity in rat assessed as inhibition of formalin-induced paw oedema at 100 mg/kg, ip after 2 hrs Rattus norvegicus 29.89 %
Antiinflammatory activity in rat assessed as inhibition of formalin-induced paw oedema at 100 mg/kg, ip after 4 hrs Rattus norvegicus 49.89 %
Antiinflammatory activity in rat assessed as inhibition of formalin-induced paw oedema at 100 mg/kg, ip after 8 hrs Rattus norvegicus 39.71 %
Antiinflammatory activity in rat assessed as inhibition of formalin-induced paw oedema at 100 mg/kg, ip after 12 hrs Rattus norvegicus 22.17 %
Antiinflammatory activity in rat assessed as inhibition of formalin-induced paw oedema at 100 mg/kg, ip after 24 hrs Rattus norvegicus 17.45 %
Antiinflammatory activity against carrageenan-induced paw edema in Albino rat assessed as oedema inhibition relative to control at 20 mg/kg, po Rattus norvegicus 29.5 %
Antiinflammatory activity against carrageenan-induced paw edema in Albino rat assessed as oedema inhibition relative to control at 40 mg/kg, po Rattus norvegicus 30.5 %
Antiinflammatory activity against carrageenan-induced paw edema in Albino rat assessed as oedema inhibition relative to control at 80 mg/kg, po Rattus norvegicus 55.1 %
Inhibition of rabbit microsomal COX at 10 uM Oryctolagus cuniculus 95.0 %
Inhibition of xylene-induced ear edema in Kunming mouse at 30 mg/kg, po after 2 hrs relative to control Mus musculus 40.7 %
Analgesic activity in mouse assessed as inhibition of acetic acid induced-abdominal writhing at 200 mg/kg, ip by Koster test Mus musculus 65.7 %
Inhibition of ovine COX1 by enzyme immuno assay Ovis aries 350.0 nM
Analgesic activity in Swiss Albino mouse assessed as inhibition of acetic acid-induced writhing responses at 10 mg/kg, po after 1 hr Mus musculus 61.55 %
Antiinflammatory activity in Kunming mouse assessed as inhibition of xylene-induced ear edema at 30 mg/kg, po after 24 hrs Mus musculus 40.7 %
Antiinflammatory activity in Kunming mouse assessed as inhibition of xylene-induced ear edema at 20 mg/kg, po after 24 hrs Mus musculus 40.7 %
Inhibition of ovine COX1 by enzyme immunoassay Ovis aries 350.0 nM
Antinociceptive effect in Swiss mouse assessed as inhibition of acetic acid-induced visceral pain at 0.0001 to 30 mg/kg, ip relative to morphine Mus musculus 83.0 %
Inhibition of ovine COX1 by enzyme immuno assay Ovis aries 350.0 nM
Antiinflammatory activity in in Kunming mouse assessed as inhibition of xylene-induced ear edema at 30 mg/kg, po Mus musculus 40.7 %
Inhibition of COX1 at 100 uM None 53.0 %
Inhibition of COX2 at 100 uM None 25.0 %
Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw edema at 100 mg/kg, po Rattus norvegicus 44.0 %
Inhibition of thrombin-induced platelet aggregation in washed rabbit platelets at 0.1 mM treated 2 mins before thrombin challenge by aggregometer Oryctolagus cuniculus 15.8 %
Inhibition of thrombin-induced platelet aggregation in washed rabbit platelets at 0.5 mM treated 2 mins before thrombin challenge by aggregometer Oryctolagus cuniculus 39.4 %
Inhibition of thrombin-induced platelet aggregation in washed rabbit platelets at 1.0 mM treated 2 mins before thrombin challenge by aggregometer Oryctolagus cuniculus 53.5 %
Analgesic activity in rat assessed as inhibition of writhing at 100 mg/kg Rattus norvegicus 85.0 %
Antiplatelet activity against platelet assessed as inhibition of ADP-induced platelet aggregation at 50 ug/ml by turbidimetry None 74.0 %
Antiplatelet activity against platelet assessed as inhibition of collagen-induced platelet aggregation at 50 ug/ml by turbidimetry None 72.0 %
Antiinflammatory activity against carrageenan-induced acute paw edema in albino rat assessed as reduction of edema at 20 mg/kg, po after 3 hrs relative to control Rattus norvegicus 29.9 %
Antiinflammatory activity against carrageenan-induced acute paw edema in albino rat assessed as reduction of edema at 40 mg/kg, po after 3 hrs relative to control Rattus norvegicus 38.8 %
Antiinflammatory activity against carrageenan-induced acute paw edema in albino rat assessed as reduction of edema at 80 mg/kg, po after 3 hrs relative to control Rattus norvegicus 61.4 %
Inhibition of rabbit distal colon cyclooxygenase at 10 uM Oryctolagus cuniculus 99.0 %
Inhibition of rat PLA2 using [14C]oleate labeled autoclaved Escherichia coli at 10 ug Rattus norvegicus 90.0 %
Inhibition of ovine COX1 by enzyme immuno assay Ovis aries 300.0 nM
Inhibition of ADP-induced New Zealand rabbit platelet aggregation at 2 mM treated for 1 min prior to ADP challenge by turbidimetric method relative to control Oryctolagus cuniculus 24.8 %
Inhibition of ovine COX1 Ovis aries 350.0 nM
Antiplatelet activity in human citreated platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated before arachidonic acid challenge Homo sapiens 32.5 ug.mL-1
Antiplatelet activity in human citreated platelet rich plasma assessed as inhibition of adenosine diphosphate-induced platelet aggregation preincubated before adenosine diphosphate challenge Homo sapiens 21.5 ug.mL-1
Antiplatelet activity in human citreated platelet rich plasma assessed as inhibition of adrenaline-induced platelet aggregation preincubated before adrenaline challenge Homo sapiens 11.7 ug.mL-1
Inhibition of ovine COX1 by enzyme immunoassay Ovis aries 300.0 nM
Antiinflammatory activity against carrageenan-induced rat inflammation model assessed as inhibition of paw edema at 714 umol/kg, po after 3 hrs Rattus norvegicus 50.0 %
Inhibition of prostaglandin synthesis in bovine seminal vesicle microsomes using [14C]arachidonic acid Bos taurus 200.0 ug.mL-1
Antiplatelet activity against washed rabbit platelet assessed as inhibition of thrombin-induced platelet aggregation at 50 ug/mL preincubated 3 mins before thrombin challenge by turbidimetric method Oryctolagus cuniculus 94.2 %
Antiplatelet activity against washed rabbit platelet assessed as inhibition of arachidonic acid-induced platelet aggregation at 50 ug/mL preincubated 3 mins before arachidonic acid challenge by turbidimetric method Oryctolagus cuniculus 7.8 %
Antiplatelet activity against washed rabbit platelet assessed as inhibition of arachidonic acid-induced platelet aggregation at 20 ug/mL pre-incubated 3 mins before arachidonic acid challenge by turbidimetric method Oryctolagus cuniculus 11.7 %
Antiplatelet activity against washed rabbit platelet assessed as inhibition of collagen-induced platelet aggregation at 50 ug/mL pre-incubated 3 mins before collagen challenge by turbidimetric method Oryctolagus cuniculus 88.4 %
Antiplatelet activity against washed rabbit platelet assessed as inhibition of platelet activating factor-induced platelet aggregation at 50 ug/mL preincubated 3 mins before PAF challenge by turbidimetric method Oryctolagus cuniculus 91.2 %
Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 20 mg/kg, po administered 30 mins prior to challenge relative to control Rattus norvegicus 30.4 %
Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 40 mg/kg, po administered 30 mins prior to challenge relative to control Rattus norvegicus 35.5 %
Antiinflammatory activity in albino rat assessed as inhibition of carrageenan-induced paw edema at 80 mg/kg, po administered 30 mins prior to challenge relative to control Rattus norvegicus 59.6 %
Inhibition of cyclooxygenase in rabbit colon microsomes assessed as reduction in conversion of arachidonic acid to PGE2 at 10 uM by liquid scintillation spectrometry relative to control Oryctolagus cuniculus 65.0 %
Inhibition of arachidonic acid-induced platelet aggregation in Sprague-Dawley rat platelet-rich plasma at 100 uM by turbidimetric method Rattus norvegicus 14.0 %
Inhibition of ovine COX1 by enzyme immuno assay Ovis aries 350.0 nM
Inhibition of arachidonic acid-induced platelet aggregation in Sprague-Dawley rat platelet-rich plasma at 10 mM by turbidimetric method Rattus norvegicus 97.0 %
Inhibition of sheep COX1 at 180 ug/mL Ovis aries 52.13 %
Inhibition of arachidonic acid-induced rabbit platelet aggregation at 100 ug/ml Oryctolagus cuniculus 0.0 %
Inhibition of collagen-induced rabbit platelet aggregation at 100 ug/ml Oryctolagus cuniculus 87.8 %
Inhibition of platelet-activating factor-induced rabbit platelet aggregation at 100 ug/ml Oryctolagus cuniculus 90.4 %
Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced right paw edema at 600 mg/kg after 1 hr Rattus norvegicus 92.4 %
Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced right paw edema at 600 mg/kg after 3 hrs Rattus norvegicus 77.3 %
Antinociceptive activity in Swiss mouse assessed as reduction of acetic acid-induced abdominal constructions at 1 to 10 mg/kg, ip administered 30 mins before acetic acid challenge measured after 20 mins relative to control Mus musculus 83.0 %
Antinociceptive activity in Swiss mouse assessed as reduction of formalin-induced inflammatory pain at 1 to 10 mg/kg, ip administered 60 mins before formalin challenge measured during 15 to 30 mins relative to control Mus musculus 88.0 %
Antiplatelet activity against citreated rabbit platelet-rich plasma assessed as inhibition of thrombin-induced platelet aggregation at 150 uM by turbidimetric method Oryctolagus cuniculus 82.7 %
Antiplatelet activity against citreated rabbit platelet-rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation at 150 uM by turbidimetric method Oryctolagus cuniculus 71.6 %
Antiplatelet activity against citreated rabbit platelet-rich plasma assessed as arachidonic acid-induced platelet aggregation at 150 uM by turbidimetric method Oryctolagus cuniculus 21.6 %
Antiplatelet activity against citreated rabbit platelet-rich plasma assessed as inhibition of ADP-induced platelet aggregation at 150 uM by turbidimetric method Oryctolagus cuniculus 92.1 %
Antiplatelet activity against citreated rabbit platelet-rich plasma assessed as inhibition of collagen-induced platelet aggregation at 150 uM by turbidimetric method Oryctolagus cuniculus 77.7 %
Inhibition of PAF-induced platelet aggregation at 2.4 mmol/L None 44.9 %
Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy Homo sapiens -5.7 %
Antinociceptive activity against acetic acid-induced abdominal constrictions in Swiss mouse assessed as maximal inhibition at 10 mg/kg, ip pretreated 30 mins before acetic acid challenge Mus musculus 35.0 %
Inhibition of COX1 at 1000 uM None 46.0 %
Inhibition of COX2 at 1000 uM None 6.0 %
Inhibition of COX1 at 180 ug/mL None 52.0 %
Analgesic activity in Swiss albino mouse assessed as inhibition of acetic acid-induced writhing at 100 mg/kg, po administered 60 mins before acetic acid challenge after 5 to 15 mins relative to control Mus musculus 61.55 %
Inhibition of ovine COX1 by enzyme immuno assay Ovis aries 350.0 nM
Analgesic activity in albino mouse assessed as inhibition of acetic acid-induced writhing response at 30 mg/kg, po administered 1 hr prior to acetic acid challenge relative to control Mus musculus 44.8 %
Analgesic activity in albino mouse assessed as inhibition of acetic acid-induced writhing response at 60 mg/kg, po administered 1 hr prior to acetic acid challenge relative to control Mus musculus 57.9 %
Analgesic activity in albino mouse assessed as inhibition of acetic acid-induced writhing response at 90 mg/kg, po administered 1 hr prior to acetic acid challenge relative to control Mus musculus 38.6 %
Antiplatelet activity in human platelets assessed as inhibition of arachidonic acid-induced platelet aggregation Homo sapiens 350.0 nM
Antiinflammatory activity in human neutrophils assessed as respiratory burst inhibition at 1000 ug/ml by WST-1 assay Homo sapiens 70.45 %
Antiinflammatory activity in human neutrophils assessed inhibition of superoxide anions production Homo sapiens 279.44 ug.mL-1
Inhibition of ovine COX-1 assessed as inhibition of transformation of AA to PGH2 by EIA Ovis aries 411.0 nM
Inhibition of potato LOX-5 assessed as inhibition of hydroperoxide production after 5 mins by EIA Solanum tuberosum 162.0 nM
Inhibition of bovine COX-1 by enzyme immuno assay Bos taurus 350.0 nM
Antiinflammatory activity against carrageenan-induced paw edema in rat at 150 mg/kg, po administered 1 hr before carrageenan challenge measured after 4 hrs by plethysmometer Rattus norvegicus 30.0 %
Antiinflammatory activity against carrageenan-induced paw edema in rat at 150 mg/kg, po administered 1 hr before carrageenan challenge measured after 6 hrs by plethysmometer Rattus norvegicus 31.0 %
Analgesic activity in BALB/c mouse assessed as decrease in acetic acid-induced writhing at 200 mg/kg, po administered 1 hr prior to acetic acid challenge by Koster's test Mus musculus 54.4 %
Inhibition of ovine COX1 by enzyme immunoassay Ovis aries 300.0 nM
Antinociceptive activity in Swiss mouse by inhibition of acetic acid-induced abdominal constriction at 10 mg/kg, ip after 20 mins Mus musculus 35.0 %
Inhibition of ovine COX2 at 1 mM by colorimetric assay Ovis aries 35.11 %
Inhibition of ovine COX1 by enzyme immunoassay Ovis aries 300.0 nM
Antiinflammatory activity in ICR mouse assessed as inhibition of xylene-induced ear edema at 165 umol/kg, po Mus musculus 65.08 %
Analgesic activity in Swiss albino mouse assessed as p-benzoquinone-induced writhing at 100 mg/kg, po administered 60 mins before benzoquinone challenge Mus musculus 51.9 %
Inhibition of sheep COX1 by enzyme immunoassay Ovis aries 300.0 nM
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, after 1 hr Rattus norvegicus 64.23 %
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 5 mg/kg, after 1 hr Rattus norvegicus 89.82 %
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 1 mg/kg, after 1 hr Rattus norvegicus 25.26 %
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, after 2 hrs Rattus norvegicus 52.06 %
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 5 mg/kg, after 2 hrs Rattus norvegicus 72.45 %
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 1 mg/kg, after 2 hrs Rattus norvegicus 19.17 %
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, after 3 hrs Rattus norvegicus 51.37 %
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 5 mg/kg, after 3 hrs Rattus norvegicus 66.21 %
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 1 mg/kg, after 3 hrs Rattus norvegicus 42.38 %
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, after 4 hrs Rattus norvegicus 1.43 %
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 5 mg/kg, after 4 hrs Rattus norvegicus 12.6 %
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 1 mg/kg, after 4 hrs Rattus norvegicus 28.8 %
Antinociceptive activity in Swiss mouse assessed as inhibition of formalin-induced paw licking activity at 10 mg/kg, ip administered 30 mins before formalin challenge measured after 5 mins Mus musculus 16.0 %
Antinociceptive activity in Swiss mouse assessed as inhibition of formalin-induced paw licking activity at 10 mg/kg, ip administered 30 mins before formalin challenge measured after 15 to 30 mins Mus musculus 45.0 %
Antinociceptive activity in Swiss mouse assessed as inhibition of acetic acid-induced writhing at 10 mg/kg, ip administered 30 mins before acetic acid challenge measured after 20 mins relative to control Mus musculus 35.0 %
Antinociceptive activity in Swiss mouse assessed as inhibition of acetic acid-induced abdominal contraction at 0.1 to 100 mg/kg, ip administered 30 mins before acetic acid challenge measured after 20 mins relative to control Mus musculus 83.0 %
Antiaggregatory activity in human platelets assessed as inhibition of collagen-induced platelet aggregation by aggregometry Homo sapiens 13.58 ug.mL-1
Antiaggregatory activity in human platelets assessed as inhibition of thrombin-induced platelet aggregation by aggregometry Homo sapiens 50.0 ug.mL-1
Antiinflammatory activity in ICR mouse assessed as inhibition of xylene-induced ear edema at 10 mmol/kg, po administered 30 mins before xylene challenge measured after 2 hrs relative to control Mus musculus 45.1 %
Antiplatelet activity in rabbit platelet rich plasma assessed as inhibition of ADP-induced aggregation at 1 mM treated for 5 mins before ADP challenge by turbidimetry Oryctolagus cuniculus 68.5 %
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 120 mg/kg, administered intragastrically immediately after carrageenan challenge measured after 3 hrs by water plethysmometer relative to control Rattus norvegicus 43.0 %
Antiinflammatory activity in po dosed rat assessed as inhibition of carrageenan-induced hind paw edema measured after 3 hrs post dose Rattus norvegicus 128.7 %
Inhibition of ovine COX1 by enzyme immuno assay Ovis aries 300.0 nM
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 150 mg/kg, po administered 1 hr before carrageenan challenge measured after 3 hrs relative to vehicle treated control Rattus norvegicus 38.0 %
Inhibition of COX1 at 100 uM None 38.0 %
Inhibition of COX2 at 100 uM None 2.0 %
Inhibition of ADP-induced platelet aggregation in Sprague-Dawley rat blood at 125.3 umol/kg, po treated for 24 hrs before ADP challenge by aggregometry method Rattus norvegicus 52.0 %
Inhibition of arachidonic acid-induced aggregation in Sprague-Dawley rat blood at 50.6 umol/kg, po treated for 24 hrs before arachidonic acid challenge by aggregometry method Rattus norvegicus 55.0 %
Antiplatelet activity in human whole blood assessed as inhibition of ADP-induced platelet aggregation at 10 ug/ml treated for 2 mins before ADP challenge measured after 6 mins by whole blood aggregometer Homo sapiens 37.55 %
Inhibition of ovine COX1 Ovis aries 300.0 nM
Inhibition of ovine COX-1 by enzyme immuno assay Ovis aries 350.0 nM
Inhibition of COX1 at 400 uM after 5 mins by spectrophotometric analysis None 38.4 %
Inhibition of COX2 at 400 uM after 5 mins by spectrophotometric analysis None 19.3 %
Inhibition of ovine COX1 at 10 uM by ELISA Ovis aries 29.0 %
Antiinflammatory activity in ICR mouse assessed as inhibition of xylene-induced ear edema at 100 mg/kg, po administered 30 mins before xylene challenge relative to control Mus musculus 89.5 %
Inhibition of adenosine diphosphate-induced platelet aggregation in rabbit platelet rich plasma at 0.1 mM by Born's turbidimetric method Oryctolagus cuniculus 10.82 %
Inhibition of arachidonic acid-induced platelet aggregation in rabbit platelet rich plasma at 0.1 mM by Born's turbidimetric method Oryctolagus cuniculus 37.2 %
Antiinflammatory activity in Kunming mouse assessed as inhibition of xylene-induced ear edema at 50 mg/kg, po administered for 3 days followed by xylene-challenge at 2 hrs post-last dose measured after 1 hr relative to vehicle-treated control Mus musculus 31.9 %
Inhibition of Ovis aries (sheep) COX2 at 1 mM after 5 min by colorimetric analysis Ovis aries 38.54 %
Inhibition of Ovis aries (sheep) COX2 at 1 uM after 5 min by colorimetric analysis Ovis aries 36.93 %
Analgesic activity in Mus musculus BALB/c (mouse) assessed as inhibition of acetic acid-induced writhing at 100 mg/kg, po administered 1 hr followed by acetic acid challenge measured for 10 min Mus musculus 50.0 %
Analgesic activity in Mus musculus Swiss albino (mouse) assessed as inhibition of acetic acid-induced writhing at 10 mg/kg, po administered 30 min prior challenge measured after 5 min of challenge for next 30 min relative to control Mus musculus 88.88 %
Analgesic activity in Mus musculus Swiss albino (mouse) assessed as inhibition of p-benzoquinone-induced writhing at 100 mg/kg, po pretreated 60 min before p-benzoquinone challenge Mus musculus 50.1 %
Anticonvulsant activity in Mus musculus MFI (mouse) assessed as inhibition of PBQ-induced writhing at 100 mg/kg, ip administered 1.5 hr prior to PBQ-challenge measured after 10 min relative to control Mus musculus 100.0 %
Anti-inflammatory activity against xylene-induced ear swelling Mus musculus (mouse) model as suppression of ear swelling at 1.11 mmol/kg, ig measured 1 hr after xylene challenge Mus musculus 45.19 %
Analgesic activity in Swiss albino Mus musculus (mouse) assessed as inhibition of p-benzoquinone-induced writhing at 100 mg/kg, po administered 60 min prior to p-benzoquinone-challenge measured up to 15 min relative to control Mus musculus 45.9 %
Inhibition of ovine COX1 Ovis aries 350.0 nM
Analgesic activity in rat at 25 mg/kg, po after 60 mins by radiant heat tail flick method relative to control Rattus norvegicus 119.0 %
Inhibition of COX-1 in human MDA-MB-231 cells assessed as inhibition of arachidonic acid-induced PGE2 formation at 100 uM incubated for 30 mins prior to arachidonic acid challenge measured after 30 mins by radioimmunoassay relative to vehicle-treated control Homo sapiens 60.0 %
Inhibition of COX-1 in human THP1 cells assessed as inhibition of arachidonic acid-induced TXB2 formation at 100 uM incubated for 30 mins prior to arachidonic acid challenge measured after 30 mins by radioimmunoassay relative to vehicle-treated control Homo sapiens 90.0 %
Antinociceptive activity in mouse assessed as inhibition of acetic acid-induced writhing response at 100 umol/kg, po after 10 mins measured for 10 mins Mus musculus 31.2 %
Antinociceptive activity in mouse assessed as inhibition of acetic acid-induced writhing response at 100 umol/kg, ip after 10 mins measured for 10 mins Mus musculus 59.0 %
Antinociceptive activity in mouse assessed as inhibition of acetic acid-induced writhing response at 15 mg/kg, ip after 10 mins measured for 10 mins Mus musculus 62.3 %
Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM Cricetulus griseus 96.37 %
Antineuroinflammatory activity in rat brain neonatal microglia Rattus norvegicus 3.2 nM
Antiplatelet activity against New Zealand white rabbit platelets assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated at 100 uM for 2 mins before challenge measured after 2 mins by spectrophotometry Oryctolagus cuniculus 99.7 %
Analgesic activity in mouse assessed as inhibition of acetic acid-induced writhing at 200 mg/kg, ig administered 1 hr before acetic acid challenge measured after 15 mins Mus musculus 71.82 %
Analgesic activity in Swiss albino mouse assessed as inhibition of acetic acid-induced writhing response at 100 mg/kg, po administered 1 hr before acetic acid challenge after 5 mins Mus musculus 63.15 %
Inhibition of epinephrine hydrochloride-induced platelet aggregation in human platelet-rich plasma after 5 mins Homo sapiens 18.0 mg kg-1
Analgesic activity in Swiss albino mouse assessed as inhibition of phenyl-p-benzoquinone-induced writhing at 50 mg/kg, sc administered 30 mins prior challenge relative to vehicle-treated control Mus musculus 50.0 %
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 200 mg/kg, po administered 30 mins prior challenge measured after 3 hrs relative to placebo-control Rattus norvegicus 65.3 %
Antiinflammatory activity in fasted male rat assessed as decrease in carrageenan-induced pleural fluid at 316 mg/kg, po after 5 hrs by Evans blue carrageenan pleural effusion assay relative to control Rattus norvegicus 31.6 %
Analgesic activity in mouse assessed as inhibition of acetic acid-induced writhing at 100 mg/kg, po administered 60 mins prior challenge measured for 5 to 10 mins post acetic acid challenge relative to control Mus musculus 72.23 %
Antiinflammatory activity in Holtzman rat assessed as inhibition of carrageenan-induced paw edema at 50 mg/kg, po administered at 0.5 and 2.5 hrs prior to carrageenan-challenge relative to control Rattus norvegicus 20.0 %
Antiinflammatory activity in Holtzman rat assessed as inhibition of UV radiation-induced erythema at 50 mg/kg, po relative to control Rattus norvegicus 50.0 %
Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 200 mg/kg, po administered 30 mins prior to 1%, sc carrageenan challenge measured after 3 hrs Rattus norvegicus 60.0 %
Antiinflammatory activity in rat assessed as inhibition of carrageenin-induced foot edema at 100 mg/kg, po Rattus norvegicus 50.0 %
Antiinflammatory activity in Wistar rat assessed as inhibition of cotton pellet-induced granuloma formation at 100 mg/kg, po after 5 days relative to control Rattus norvegicus 5.0 %
Antiinflammatory activity in rat assessed as inhibition of carrageenan-induced paw edema at 300 mg/kg, po relative to control Rattus norvegicus 31.0 %
Antiplatelet activity in Sprague-Dawley rat assessed as inhibition of TXB2 formation at 30 mg/kg, po od after 7 days by EIA relative to vehicle-treated control Rattus norvegicus 75.97 %
Antiinflammatory activity against ICR mouse ear edema model assessed as inhibition of xylene-induced edema at 100 mg/kg, po administered 30 mins prior to xylene challenge measured after 2 hrs relative to vehicle-treated control Mus musculus 89.5 %
Anti-platelet activity in rat platelet rich plasma assessed as inhibition of ADP and calcium-induced platelet aggregation at 1650 uM incubated at 37 degC for 10 mins and measured 30 mins after ADP and calcium addition Rattus norvegicus 41.48 %
Antiplatelet activity in rabbit platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation at 0.1 mM preincubated for 5 mins followed by arachidonic acid addition measured after 5 mins by Born's turbidimetric method relative to control Oryctolagus cuniculus 16.16 %
Induction of NO production in Wistar rat at 1 to 10 mg/kg, po qd administered for 7 days measured after 1 hr post last dose by enzyme immuno assay Rattus norvegicus 64.0 %
Antiinflammatory activity in ICR mouse assessed as inhibition of xylene-induced ear edema at 0.1 umol/kg, po administered 30 mins prior to xylene challenge measured after 2hrs Mus musculus 49.9 %
Inhibition of ovine COX-1 assessed as reduction in PGF2-alpha formation using arachidonic acid as substrate by enzyme immunoassay Ovis aries 300.0 nM
Anti-inflammatory activity in ICR mouse assessed as inhibition of xylene-induced ear edema at 1 umol/kg, po pretreated for 30 mins followed by xylene administration measured after 2 hrs relative to control Mus musculus 50.3 %
Inhibition of ovine COX-1 assessed as reduction in PGG2 production using ADHP as substrate at 2 uM incubated for 5 mins followed by substrate addition measured after 2 mins by fluorescence assay Ovis aries 31.0 %
Inhibition of ovine COX-1 assessed as reduction in PGG2 production using ADHP as substrate at 200 uM incubated for 5 mins followed by substrate addition measured after 2 mins by fluorescence assay Ovis aries 36.0 %
Antiinflammatory activity in rat carrageenan-induced paw edema model assessed as inhibition of paw swelling at 25 mg/kg, ip administered 30 mins prior to carrageenan challenge measured after 3 hrs Rattus norvegicus 30.6 %
Antiinflammatory activity in rat carrageenan-induced paw edema model assessed as inhibition of paw swelling at 25 mg/kg, ip administered 30 mins prior to carrageenan challenge measured after 5 hrs Rattus norvegicus 29.4 %
Anti-inflammatory activity in para-xylene-induced Kunming mouse ear-swelling model assessed as inhibition of ear swelling at 100 mg/kg, ig measured after 1 hr relative to control Mus musculus 64.91 %
Inhibition of COX2 expression in HCA-7 cells at 1 mM after 48 hrs by Western blot method relative to control Homo sapiens 12.0 %
Inhibition of COX2 in HCA-7 cells assessed as reduction in PGE2 release at 1 mM after 48 hrs by ELISA relative to control Homo sapiens 19.0 %
Anti-inflammatory activity in ICR mouse assessed as inhibition of xylene induced ear edema at 20 mg/kg pretreated orally for 30 mins followed by xylene challenge measured after 2 hrs relative to control Mus musculus 47.08 %
Antiplatelet activity in Wistar rat platelet rich plasma assessed as inhibition of collagen-induced platelet aggregation at 150 uM preincubated for 1 min followed by collagen addition by aggregometric analysis relative to control Rattus norvegicus 63.4 %
Antiplatelet activity in Wistar rat platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation at 150 uM preincubated for 1 min followed by arachidonic acid addition by aggregometric analysis relative to control Rattus norvegicus 28.9 %
Antiplatelet activity in Wistar rat platelet rich plasma assessed as inhibition of ADP-induced platelet aggregation at 150 uM preincubated for 1 min followed by ADP addition by aggregometric analysis relative to control Rattus norvegicus 27.7 %
Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation at 100 uM preincubated for 2 mins followed by arachidonic acid addition by turbidimetric method relative to control Homo sapiens 96.6 %
Antiplatelet activity in human platelet rich plasma assessed as inhibition of ADP-induced platelet aggregation at 100 uM preincubated for 2 mins followed by ADP addition by turbidimetric method relative to control Homo sapiens 41.85 %
Antiplatelet activity in human platelet rich plasma assessed as inhibition of collagen-induced platelet aggregation at 100 uM preincubated for 2 mins followed by collagen addition by turbidimetric method relative to control Homo sapiens 85.32 %
Antiplatelet activity in human platelet rich plasma assessed as inhibition of epinephrine-induced platelet aggregation at 100 uM preincubated for 2 mins followed by epinephrine addition by turbidimetric method relative to control Homo sapiens 58.65 %
Antiplatelet activity in human platelet rich plasma assessed as inhibition of ADP-induced platelet aggregation at 150 uM preincubated for 5 mins followed by ADP addition measured after 5 mins by Borns turbidimetric method Homo sapiens 28.11 %
Antiplatelet activity in human platelet rich plasma assessed as inhibition of ADP-induced platelet aggregation at 15 uM preincubated for 5 mins followed by ADP addition measured after 5 mins by Borns turbidimetric method Homo sapiens 12.44 %
Antiplatelet activity in human platelet rich plasma assessed as inhibition of ADP-induced platelet aggregation at 1.5 uM preincubated for 5 mins followed by ADP addition measured after 5 mins by Borns turbidimetric method Homo sapiens 5.96 %
Anti-inflammatory activity in human RBC membranes assessed as inhibition of heat-induced hemolysis at 100 ug/mL incubated for 20 mins at 54 degC by UV-VIS spectrometer analysis relative to control Homo sapiens 36.16 %
Inhibition of ROS generation in human PMN at 0.78 ug/ml after 50 mins by luminol-based chemiluminescence assay relative to control Homo sapiens 33.0 %
Inhibition of ROS generation in human PMN at 1.56 ug/ml after 50 mins by luminol-based chemiluminescence assay relative to control Homo sapiens 46.0 %
Inhibition of ROS generation in human PMN at 3.13 ug/ml after 50 mins by luminol-based chemiluminescence assay relative to control Homo sapiens 63.0 %
Inhibition of ROS generation in human PMN at 6.25 ug/ml after 50 mins by luminol-based chemiluminescence assay relative to control Homo sapiens 85.0 %
Inhibition of ROS generation in human PMN at 12.5 ug/ml after 50 mins by luminol-based chemiluminescence assay relative to control Homo sapiens 92.0 %
Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation at 100 uM preincubated for 5 mins followed by arachidonic acid addition measured for 3 mins by aggregometric analysis relative to control Homo sapiens 100.0 %
Antiplatelet activity in human platelet rich plasma assessed as inhibition of collagen-induced platelet aggregation at 100 uM preincubated for 5 mins followed by arachidonic acid addition measured for 3 mins by aggregometric analysis relative to control Homo sapiens 100.0 %
Antiplatelet activity in Wistar rat platelet rich plasma assessed as inhibition of ADP-induced platelet aggregation at 100 uM pretreated for 1 min followed by ADP addition by turbidimetric method relative to control Rattus norvegicus 5.0 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging Homo sapiens 13.13 %
Inhibition of ADP-induced platelet aggregation in human platelet-rich plasma at 0.1 mM preincubated for 5 mins followed by ADP-stimulation and measured within 5 mins by Born's turbidimetric analysis relative to control Homo sapiens 26.03 %
Antiinflammatory activity in Wistar rat assessed as inhibition of cotton pellet-induced granuloma at 75 mg/kg, po administered daily for 7 days and measured on day 8 relative to control Rattus norvegicus 30.1 %
Antiinflammatory activity in Wistar rat model of Freund's adjuvant-induced arthritis assessed as inhibition of arthritis by measuring reduction in paw volume at 75 mg/kg, po administered once daily for 8 days starting from day 7 post Freund's adjuvant treatment and measured after 18 days by mercury plethysmography relative to control Rattus norvegicus 40.0 %
Antiinflammatory activity in Swiss mouse assessed as inhibition of TPA-induced ear edema at 1 mg/ear applied topically and measured 4 hrs post-TPA challenge relative to control Mus musculus 20.1 %
Antiplatelet activity in rabbit platelet rich plasma assessed as inhibition of collagen-induced platelet aggregation at 300 uM preincubated for 3 mins followed by collagen addition measured after 10 mins relative to control Oryctolagus cuniculus 5.8 %
Antiplatelet activity in rabbit platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation at 300 uM preincubated for 3 mins followed by arachidonic acid addition measured after 10 mins relative to control Oryctolagus cuniculus 100.0 %
Antiplatelet activity in rabbit platelet rich plasma assessed as inhibition of PAF-induced platelet aggregation at 300 uM preincubated for 3 mins followed by PAF addition measured after 10 mins relative to control Oryctolagus cuniculus 0.3 %
Antiplatelet activity in rabbit platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation at 150 uM preincubated for 3 mins followed by arachidonic acid addition measured after 10 mins relative to control Oryctolagus cuniculus 75.0 %
Antiplatelet activity in rabbit platelet rich plasma assessed as inhibition of PAF-induced platelet aggregation at 150 uM preincubated for 3 mins followed by PAF addition measured after 10 mins relative to control Oryctolagus cuniculus 0.3 %
Inhibition of NAPRT (unknown origin) Homo sapiens 0.5 nM
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 7.548 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.05 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.05 %
Analgesic activity in mouse model of acetic-acid-induced writhing assessed as inhibition of writhing numbers at 200 mg/kg, po pretreated with compound followed by acetic acid challenge and measured after 30 mins relative to control Mus musculus 51.54 %
Antiplatelet activity in rat platelet-rich plasma assessed as inhibition of ADP-induced platelet aggregation at 33 uM preincubated for 30 mins followed by ADP addition measured within 5 mins by aggregometry relative to control Rattus norvegicus 12.4 %
Inhibition of COX1 (unknown origin) Homo sapiens 350.0 nM
Inhibition of Ovine COX-1 assessed as decrease in prostaglandin production using arachidonic acid as substrate pretreated for 15 mins followed by substrate addition and measured after 2 mins by enzyme immunoassay Ovis aries 300.0 nM
Antiinflammatory activity against carrageenan-induced paw edema in Swiss mouse assessed as inhibition of paw edema at 100 mg/kg administered 30 mins prior to carrageenan challenge and measured after 1 hr by paleothermometric-method (Rvb = 7.66 +/- 3.753%) Mus musculus 47.54 %
Antiinflammatory activity against carrageenan-induced paw edema in Swiss mouse assessed as inhibition of paw edema at 100 mg/kg administered 30 mins prior to carrageenan challenge and measured after 2 hrs by paleothermometric-method (Rvb = 7.39 +/- 2.475%) Mus musculus 54.63 %
Antiinflammatory activity against carrageenan-induced paw edema in Swiss mouse assessed as inhibition of paw edema at 100 mg/kg administered 30 mins prior to carrageenan challenge and measured after 3 hrs by paleothermometric-method (Rvb = 11.41 +/- 3.069%) Mus musculus 53.26 %
Antiinflammatory activity against carrageenan-induced paw edema in Swiss mouse assessed as inhibition of paw edema at 100 mg/kg administered 30 mins prior to carrageenan challenge and measured after 4 hrs by paleothermometric-method (Rvb = 14.46 +/- 1.568%) Mus musculus 56.92 %
Antiinflammatory activity against carrageenan-induced paw edema in Swiss mouse assessed as inhibition of paw edema at 100 mg/kg administered 30 mins prior to carrageenan challenge and measured after 5 hrs by paleothermometric-method (Rvb = 7.31 +/- 3.204%) Mus musculus 57.64 %
Antiinflammatory activity in leukotriene-induced paw edema in Balb/c mouse assessed as inhibition of paw edema at 25 mg/kg, ip administered 1 hr prior to leukotriene challenge and measured after 3 hrs relative to control Mus musculus 77.4 %
Inhibition of thrombin-induced platelet aggregation in mouse platelet isolated from C57BL/6J mouse treated at 200 mg/kg, ig twice a day for 7 days by lumi-aggregometer Mus musculus 38.8 %
Anti-platelet aggregation activity in rabbit venous blood assessed as inhibition of ADP-induced aggregation at 1.3 uM pre-treated for 2 mins followed by ADP addition by Born turbidimetric method relative to control Oryctolagus cuniculus 46.3 %
Anti-platelet aggregation activity in rabbit venous blood assessed as inhibition of ADP-induced aggregation pre-treated for 2 mins followed by ADP addition by Born turbidimetric method Oryctolagus cuniculus 440.0 nM
Anti-platelet aggregation activity in rabbit venous blood assessed as inhibition of arachidonic acid-induced aggregation at 1.3 uM pre-treated for 2 mins followed by ADP addition by Born turbidimetric method relative to control Oryctolagus cuniculus 38.45 %
Anti-platelet aggregation activity in rabbit venous blood assessed as inhibition of arachidonic acid-induced aggregation pre-treated for 2 mins followed by ADP addition by Born turbidimetric method Oryctolagus cuniculus 430.0 nM
Anti-platelet aggregation activity in rabbit venous blood assessed as inhibition of collagen-induced aggregation at 1.3 uM pre-treated for 2 mins followed by ADP addition by Born turbidimetric method relative to control Oryctolagus cuniculus 49.12 %

Related Entries

Cross References

Resources Reference
ChEBI 15365
ChEMBL CHEMBL25
DrugBank DB00945
DrugCentral 74
FDA SRS R16CO5Y76E
Human Metabolome Database HMDB0001879
Guide to Pharmacology 4139
KEGG C01405
PDB AIN
PharmGKB PA448497
PubChem 2244
SureChEMBL SCHEMBL1353
ZINC ZINC000000000053
CONTENTS